Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
人类乳腺癌中 DF3/MUC1 的致癌信号传导
基本信息
- 批准号:7527533
- 负责人:
- 金额:$ 37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-07-01 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:ApoptosisAttenuatedBindingBreast CarcinomaC-terminalCause of DeathCell NucleusCell membraneCell surfaceCellsCytosolDevelopmentEpidermal Growth Factor ReceptorEpithelial CellsExperimental ModelsExtracellular MatrixGalectin 3Gene TargetingGenetic TranscriptionGlycoproteinsGrantGrowthHeregulinHumanHuman DevelopmentMUC1 geneMalignant - descriptorMammary NeoplasmsMammary glandMitochondriaMucin-1 Staining MethodMucinsN-terminalNuclearOncogene ProteinsOncogenicOuter Mitochondrial MembranePathway interactionsPhysiologicalProtein OverexpressionProteinsPublic HealthRegulationResearchRoleSRC geneSignal PathwaySignal TransductionStressUp-RegulationWomanWorkbiological adaptation to stressinsightmalignant breast neoplasmreceptorresponsetumor growthtumorigenesis
项目摘要
DESCRIPTION (provided by applicant): The MUC1 heterodimeric oncoprotein is aberrantly expressed at high levels in over 90% of human breast cancers. The MUC1 N-terminal subunit (MUC1-N) is a mucin-type glycoprotein that disrupts cell-cell and cell-extracellular matrix interactions. The MUC1 C-terminal subunit (MUC1-C) binds to the Wnt pathway effector, ?-catenin, and functions as a transmembrane receptor. Our work has also demonstrated that MUC1 interacts with EGFR, ErbB2, c-Src and GSK32, indicating that MUC1 integrates the ErbB receptor and Wnt signaling pathways. Other studies supported by this grant have demonstrated that MUC1-C is targeted (i) to the nucleus where it functions in the regulation of gene transcription, and (ii) to mitochondria where it attenuates permeabilization of the mitochondrial outer membrane. These findings have provided new insights into the potential role of MUC1 in the development of human breast carcinomas. What is needed now, at least in part, is a more precise understanding of the biologic significance of MUC1 in breast cancer. Our hypothesis is that MUC1 functions physiologically in the protection of normal mammary epithelial cells and that the MUC1 gene is activated by the heregulin (HRG)-induced stress response. Our hypothesis is also that the MUC1-C subunit transduces signals from the cell membrane to the nucleus and mitochondria that confer a growth and survival response to stress. The overexpression of MUC1 as found in most human breast cancers is therefore proposed as a mechanism by which physiologic MUC1 functions have been exploited in the aberrant regulation of tumor growth and survival. The Specific Aims are: 1) To define the role of Muc1 in mammary gland tumorigenesis; 2) To elucidate the mechanisms responsible for upregulation of MUC1 expression in nontransformed and malignant mammary epithelial cells; 3) To determine the functional significance of the interaction between MUC1 and galectin-3 on cell surface signaling; 4) To define the effects of nuclear MUC1-C on occupancy and activation of Wnt target genes; and 5) To assess the role of MUC1-C in restraining apoptosis in the cytosol and at the mitochondrial outer membrane.
PUBLIC HEALTH RELEVANCE: Breast cancer is one of the leading causes of death among women. The MUC1 protein contributes to the development of breast cancer in experimental models and is expressed at high levels in over 90% of human breast tumors. Our proposed research on MUC1 should provide a better understanding of the causes of breast cancer and potentially new opportunities for treatment.
描述(由申请人提供):MUC 1异二聚体癌蛋白在超过90%的人乳腺癌中以高水平异常表达。MUC 1 N-末端亚基(MUC 1-N)是破坏细胞-细胞和细胞-细胞外基质相互作用的粘蛋白型糖蛋白。MUC 1 C-末端亚基(MUC 1-C)与Wnt通路效应子结合,连环蛋白,并作为跨膜受体发挥功能。我们的工作还表明MUC 1与EGFR、ErbB 2、c-Src和GSK 32相互作用,表明MUC 1整合了ErbB受体和Wnt信号通路。该基金支持的其他研究表明,MUC 1-C靶向(i)细胞核,在那里它在基因转录的调节中发挥作用,以及(ii)线粒体,在那里它减弱线粒体外膜的透化。这些发现为MUC 1在人类乳腺癌发展中的潜在作用提供了新的见解。现在需要的是,至少在一定程度上,是对MUC 1在乳腺癌中的生物学意义的更精确的理解。我们的假设是,MUC 1的生理功能,在正常的乳腺上皮细胞的保护和MUC 1基因被激活的heregulin(HRG)诱导的应激反应。我们的假设也是MUC 1-C亚基将信号从细胞膜转导到细胞核和线粒体,从而对应激产生生长和存活反应。因此,在大多数人乳腺癌中发现的MUC 1的过表达被认为是一种机制,通过这种机制,MUC 1的生理功能被用于肿瘤生长和存活的异常调节。具体目标是:1)明确MUC 1在乳腺肿瘤发生中的作用; 2)阐明MUC 1在非转化和恶性乳腺上皮细胞中表达上调的机制; 3)确定MUC 1和半乳糖凝集素-3相互作用对细胞表面信号传导的功能意义; 4)确定核MUC 1-C对Wnt靶基因的占据和激活的影响; 5)探讨MUC 1-C在抑制细胞质和线粒体外膜凋亡中的作用。
公共卫生相关性:乳腺癌是妇女死亡的主要原因之一。MUC 1蛋白在实验模型中有助于乳腺癌的发展,并且在超过90%的人类乳腺肿瘤中以高水平表达。我们提出的MUC 1研究应该可以更好地了解乳腺癌的病因,并提供潜在的新治疗机会。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DONALD W. KUFE其他文献
DONALD W. KUFE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DONALD W. KUFE', 18)}}的其他基金
Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer
使用抗体药物偶联物靶向 MUC1-C 治疗晚期前列腺癌
- 批准号:
10512804 - 财政年份:2022
- 资助金额:
$ 37万 - 项目类别:
Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression
靶向 MUC1-C 治疗小细胞肺癌进展
- 批准号:
10354347 - 财政年份:2022
- 资助金额:
$ 37万 - 项目类别:
Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression
靶向 MUC1-C 治疗小细胞肺癌进展
- 批准号:
10563188 - 财政年份:2022
- 资助金额:
$ 37万 - 项目类别:
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
MUC1-C 是逆转免疫逃避和免疫疗法耐药性的靶点
- 批准号:
9789217 - 财政年份:2018
- 资助金额:
$ 37万 - 项目类别:
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
MUC1-C 是逆转免疫逃避和免疫疗法耐药性的靶点
- 批准号:
10004595 - 财政年份:2018
- 资助金额:
$ 37万 - 项目类别:
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
MUC1-C 是逆转免疫逃避和免疫疗法耐药性的靶点
- 批准号:
10478059 - 财政年份:2018
- 资助金额:
$ 37万 - 项目类别:
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
MUC1-C 是逆转免疫逃避和免疫疗法耐药性的靶点
- 批准号:
10224740 - 财政年份:2018
- 资助金额:
$ 37万 - 项目类别:
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
MUC1-C 癌蛋白在非小细胞肺癌中逃避免疫破坏
- 批准号:
9913473 - 财政年份:2012
- 资助金额:
$ 37万 - 项目类别:
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
MUC1-C 癌蛋白在非小细胞肺癌中逃避免疫破坏
- 批准号:
9238148 - 财政年份:2012
- 资助金额:
$ 37万 - 项目类别:
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer
MUC1-C 癌蛋白在非小细胞肺癌中的功能作用
- 批准号:
8837576 - 财政年份:2012
- 资助金额:
$ 37万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 37万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 37万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 37万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 37万 - 项目类别:
Idea to Innovation